Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities research analysts at Leerink Swann reduced their FY2020 earnings estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Friday. Leerink Swann analyst J. Schwartz now anticipates that the firm will post earnings of $0.17 per share for the year, down from their previous forecast of $0.21. Leerink Swann currently has a “Outperform” rating and a $90.00 target price on the stock.

Other equities analysts have also issued reports about the stock. Jefferies Group set a $109.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Sunday, September 18th. Credit Suisse Group AG reissued a “buy” rating and issued a $101.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, September 14th. Cowen and Company reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. JPMorgan Chase & Co. set a $110.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Monday, August 8th. Finally, Piper Jaffray Cos. set a $82.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $94.23.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 3.22% on Monday, hitting $78.81. The company had a trading volume of 363,484 shares. Ultragenyx Pharmaceutical has a 12-month low of $46.52 and a 12-month high of $117.12. The company has a 50 day moving average of $66.94 and a 200-day moving average of $63.82. The company’s market cap is $3.22 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($1.64) earnings per share for the quarter, missing the consensus estimate of ($1.53) by $0.11. During the same period last year, the firm earned ($1.03) earnings per share.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. bought a new position in Ultragenyx Pharmaceutical during the second quarter worth about $100,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Ultragenyx Pharmaceutical by 72.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,426 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 600 shares during the last quarter. First Mercantile Trust Co. increased its position in Ultragenyx Pharmaceutical by 1.7% in the third quarter. First Mercantile Trust Co. now owns 2,339 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 39 shares during the last quarter. DIAM Co. Ltd. bought a new position in Ultragenyx Pharmaceutical during the second quarter worth about $177,000. Finally, Springbok Capital Management LLC bought a new position in Ultragenyx Pharmaceutical during the first quarter worth about $189,000. Institutional investors own 93.01% of the company’s stock.

In other news, CFO Shalini Sharp sold 24,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $71.20, for a total value of $1,708,800.00. Following the transaction, the chief financial officer now owns 69,387 shares in the company, valued at approximately $4,940,354.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction on Friday, October 14th. The shares were sold at an average price of $63.02, for a total transaction of $1,260,400.00. Following the transaction, the chief executive officer now owns 480,632 shares in the company, valued at approximately $30,289,428.64. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.